Synapse - Works

Results (68)

Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial

Journal Article

Omuro, A.; Brandes, A. A.; Carpentier, A. F.; Idbaih, A.; Reardon, D. A.; Cloughesy, T.; Sumrall, A.; Baehring, J.; van den Bent, M.; Bähr, O.; more...
Neuro-Oncology (2023)

Fulltext@MSK | Save

Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter

Journal Article

Lim, M.; Weller, M.; Idbaih, A.; Steinbach, J.; Finocchiaro, G.; Raval, R. R.; Ansstas, G.; Baehring, J.; Taylor, J. W.; Honnorat, J.; more...
Neuro-Oncology (2022)

Fulltext@MSK | Save

Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance)

Journal Article

Galanis, E.; Anderson, S. K.; Twohy, E.; Butowski, N. A.; Hormigo, A.; Schiff, D.; Omuro, A.; Jaeckle, K. A.; Kumar, S.; Kaufmann, T. J.; more...
Neuro-Oncology Advances (2022)

Fulltext@MSK | Save

Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143

Journal Article

Omuro, A.; Reardon, D. A.; Sampson, J. H.; Baehring, J.; Sahebjam, S.; Cloughesy, T. F.; Chalamandaris, A. G.; Potter, V.; Butowski, N.; Lim, M.
Neuro-Oncology Advances (2022)

Fulltext@MSK | Save

Phase I and preliminary phase 0 results of ABTC 1801: A multi-arm clinical trial of the PARP inhibitor pamiparib (BGB290) with very low dose metronomic temozolomide in recurrent IDH mutant gliomas

Meeting Abstract

Schiff, D.; Bindra, R.; Li, J.; Ye, X.; Ellingson, B.; Walbert, T.; Campian, J.; Nabors, L. B.; Lieberman, F.; Ozer, B.; more...
Neuro-Oncology (2021)

Fulltext@MSK | Save

A randomized phase 3 study of nivolumab or placebo combined with radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma with methylated MGMT promoter: Checkmate 548

Meeting Abstract

Weller, M.; Lim, M.; Idbaih, A.; Steinbach, J.; Finocchiaro, G.; Raval, R.; Ashby, L.; Ansstas, G.; Baehring, J.; Taylor, J.; more...
Neuro-Oncology (2021)

Fulltext@MSK | Save

Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: Results from exploratory phase I cohorts of CheckMate 143

Journal Article

Omuro, A.; Vlahovic, G.; Lim, M.; Sahebjam, S.; Baehring, J.; Cloughesy, T.; Voloschin, A.; Ramkissoon, S. H.; Ligon, K. L.; Latek, R.; more...
Neuro-Oncology (2018)

Fulltext@MSK | Save

Nivolumab (nivo) in combination with radiotherapy (RT) +/- temozolomide (TMZ): Updated safety results from CheckMate 143 in pts with methylated or unmethylated newly diagnosed glioblastoma (GBM)

Meeting Abstract

Lim, M.; Omuro, A.; Vlahovic, G.; Reardon, D. A.; Sahebjam, S.; Cloughesy, T.; Baehring, J.; Butowski, N.; Potter, V.; Zwirtes, R.; more...
Annals of Oncology (2017)

Fulltext@MSK | Save

Cerebrospinal fluid circulating tumor cells: A novel tool to diagnose leptomeningeal metastases from epithelial tumors

Journal Article

Lin, X.; Fleisher, M.; Rosenblum, M.; Lin, O.; Boire, A.; Briggs, S.; Bensman, Y.; Hurtado, B.; Shagabayeva, L.; DeAngelis, L. M.; more...
Neuro-Oncology (2017)

Fulltext@MSK | Save

Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma

Journal Article

Thomas, A. A.; Abrey, L. E.; Terziev, R.; Raizer, J.; Martinez, N. L.; Forsyth, P.; Paleologos, N.; Matasar, M.; Sauter, C. S.; Moskowitz, C.; more...
Neuro-Oncology (2017)

Fulltext@MSK | Save